Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zeta-PC-004 is a drug candidate developed by Zetagen Therapeutics as part of their proprietary 'Zeta' oncology platform. While specific details about the mechanism of action, modality, or clinical status for Zeta-PC-004 are not publicly disclosed in available sources, it is listed among Zetagen's pipeline assets alongside other drugs such as ZetaMet (Zeta-BC-003) and ZetaMAST (Zeta-MBC-005), which are small molecule therapies designed for local administration to treat metastatic cancers, particularly those involving bone and soft tissue. The broader 'Zeta' platform focuses on suspending cancer progression, inhibiting pain, and regenerating bone with the goal of increasing survival rates in patients with advanced cancers[8]. No direct information regarding indications or trial phases for Zeta-PC-004 has been published.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zeta-PC-004.